Disclosure Quest - Search SEC Filings

Name	Type of Offering	Accepted Date
Galvanize Therapeutics, Inc. See All Filings	D	2025-09-10 20:01:14 UTC
Amount To Be Raised $141,066,486 Associated Brokers / Dealers N/A CIK Number 0001659073 Filed Document 0001659073-25-000001 Exclusions or Exemptions 506b Accepted Date 2025-09-10 20:01:14 UTC Type of Offering D Industry Biotechnology Principal Place of Business CALIFORNIA Revenue or Assets Decline to Disclose Type of Security Equity
Galvanize Therapeutics, Inc. See All Filings	D	2022-03-22 12:45:17 UTC
Amount To Be Raised $4,000,000 Associated Brokers / Dealers N/A CIK Number 0001659073 Filed Document 0001659073-22-000003 Exclusions or Exemptions 506b Accepted Date 2022-03-22 12:45:17 UTC Type of Offering D Industry Biotechnology Principal Place of Business CALIFORNIA Revenue or Assets Decline to Disclose Type of Security Debt
Galvanize Therapeutics, Inc. See All Filings	D	2022-03-09 15:39:02 UTC
Amount To Be Raised $2,000,000 Associated Brokers / Dealers N/A CIK Number 0001659073 Filed Document 0001659073-22-000002 Exclusions or Exemptions 506b Accepted Date 2022-03-09 15:39:02 UTC Type of Offering D Industry Biotechnology Principal Place of Business CALIFORNIA Revenue or Assets Decline to Disclose Type of Security Debt
Gala Therapeutics, Inc. See All Filings	D/A	2019-11-18 12:42:27 UTC
Amount To Be Raised $43,000,000 Associated Brokers / Dealers N/A CIK Number 0001659073 Filed Document 0001659073-19-000005 Exclusions or Exemptions 506b Accepted Date 2019-11-18 12:42:27 UTC Type of Offering D/A Industry Biotechnology Principal Place of Business CALIFORNIA Revenue or Assets Decline to Disclose Type of Security Equity
Gala Therapeutics, Inc. See All Filings	D	2019-03-13 16:27:18 UTC
Amount To Be Raised $28,000,000 Associated Brokers / Dealers N/A CIK Number 0001659073 Filed Document 0001659073-19-000003 Exclusions or Exemptions 506b Accepted Date 2019-03-13 16:27:18 UTC Type of Offering D Industry Biotechnology Principal Place of Business CALIFORNIA Revenue or Assets Decline to Disclose Type of Security Equity